V617F JAK2 mutation is a reliable molecular marker of polycythemia vera (PV), potentially
useful to monitor the effect of treatments in this disease. In a phase 2 study of pegylated (peg) …

Pulmonary arterial hypertension (PAH) is a life-threatening disease that can be induced by
dasatinib, a dual Src and BCR-ABL tyrosine kinase inhibitor that is used to treat chronic …

Au cours des der nières années, la ges tion de tré so re rie en entre prise a connu bien des
évo lu tions. Relé guée aux der niers rangs des pré oc cu pa tions, souvent rat ta chée à la …

Purpose More than half of patients with chronic-phase chronic myelogenous leukemia (CP-CML)
in complete molecular response (CMR) experience molecular relapse after imatinib …

Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had …

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL
tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet …

Background Imatinib treatment significantly improves survival in patients with chronic myeloid
leukaemia (CML), but little is known about whether treatment can safely be discontinued in …

The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. …

Background The results of the addition of gemtuzumab ozogamicin, an anti-CD33 antibody
conjugate, to the standard treatment for patients with acute myeloid leukaemia in phase 3 …